Sur180 Therapeutics

What Sur180 Therapeutics does

Sur180 Therapeutics is a women-centered, privately-held biotechnology startup founded in 2021 and headquartered in McAllen, Texas, with research operations conducted from Ponce, Puerto Rico via the Ponce Research Institute. The company is developing non-hormonal therapeutics for endometriosis, a condition affecting an estimated 190 million women globally and 6.5 million in the U.S., with average diagnosis delays of 7–10 years. Its core program, internally referred to as "Drug P," repositions a safe, out-of-patent small-molecule CRHR1 antagonist that was previously tested in clinical trials for mood and addiction disorders. Sur180 applies the molecule to block the corticotropin-releasing hormone receptor 1 (CRHR1) pathway within the hypothalamic-pituitary-adrenal (HPA) axis — the body's stress-response system — rather than targeting the gonadal axis addressed by conventional hormonal therapies. The company holds exclusive licensing rights to granted U.S. Patent 10,729,693 covering endometriosis compositions and methods, and jointly owns pending application US 63/688,026 covering novel gynecologic use of the CRHR1 antagonist.

The company's business model is currently grant-funded rather than revenue-generating. Sur180 has secured approximately $2.75 million in cumulative NIH funding, including a competitive ~$2.4M NICHD grant awarded in July 2025, supporting preclinical development of its lead candidate. It has no pricing model, no distribution channels, and no commercial product. The firm employs 1–10 people and operates through a small leadership team of three scientific co-founders — Dr. Annelyn Torres-Reveron (CEO), Dr. Caroline B. Appleyard (Scientific Director), and Dr. Idhaliz Flores (Chair of Scientific Board) — supplemented by research staff at the Ponce Research Institute and external advisors covering regulatory, clinical, and financial domains.

Sur180's go-to-market strategy in the near term centers on advancing preclinical evidence, expanding its intellectual property perimeter, and building research collaborations. Its March 2026 strategic partnership with Nura Health is designed to integrate precision diagnostics and biomarker-based patient subtyping with the company's therapeutic development, potentially enabling a stratified-treatment approach. The company's primary customer segment is women of reproductive age suffering from endometriosis who seek long-term pain relief, disease modification, fertility preservation, and avoidance of the menopausal side effects associated with current hormonal therapies. End-customer revenue, pricing, and channel decisions remain undefined pending clinical advancement.

Name

Sur180 Therapeutics

Legal name

Sur180 Therapeutics

Website

https://sur180therapeutics.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Sur180 Therapeutics is a pre-clinical, women-led biotech founded in 2021 that is developing a non-hormonal, repositioned CRHR1 antagonist to treat endometriosis by targeting the HPA stress-response axis rather than the gonadal axis, targeting an estimated 6.5 million U.S. patients.

Ownership category

akta.pro rank

Product category

Endometriosis Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industry

Endocrine Hypertension & Neuroendocrine Disorders (HLAKADAN)

Keywords

• Non-hormonal endometriosis therapeutics
• CRHR1 antagonist drugs
• Women's health biotech
• Endometriosis drug development
• Small-molecule drug repositioning

Headquarters

HQ city

Mcallen

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Marketing channels5 records

Core offering

Sur180 Therapeutics is developing a non-hormonal small-molecule drug candidate (Drug P), a CRHR1 antagonist being repositioned for the treatment of endometriosis. The therapy targets the hypothalamic-pituitary-adrenal (HPA) stress-response axis rather than the traditional gonadal axis to relieve pain and potentially slow disease progression without hormone suppression or impact on fertility. The product is in preclinical/clinical development and is not yet commercialized.

Product overview

Sur180 Therapeutics is a biotechnology company developing non-hormonal therapeutics for endometriosis. The company's flagship product is a novel CRHR1 antagonist (Drug P) that targets the stress-response pathway (HPA axis) rather than the gonadal axis, providing pain relief and potentially slowing disease progression without hormone suppression or impact on fertility. The company also offers research partnerships, such as the strategic collaboration with Nura Health to integrate precision diagnostics with their therapeutic development.

Differentiator

Problem solved

Functional benefit

Products and services

• CRHR1 Antagonist (Drug P) — Non-Hormonal Therapeutic for Endometriosis A non-hormonal small-molecule CRHR1 antagonist being repositioned for endometriosis to block the HPA axis stress-response pathway, intended to relieve pain and potentially slow disease progression without hormone suppression or impact on fertility. The molecule was previously tested in clinical trials for mood and addiction disorders with no safety concerns, and Sur180 holds exclusive licensing rights to a granted U.S. endometriosis treatment patent plus a pending provisional covering its novel gynecologic use.

Quantifiable outcome

• Significant benefit demonstrated in reducing endometriosis lesion size and inflammation in preclinical studies
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core.

• Nura HealthcoreStrategic or Co-development Partner · 17 March 2026Strategic research partnership to integrate precision diagnostics with non-hormonal therapeutics for endometriosis. The collaboration coordinates research workflows, data-sharing, biomarker analytics, and clinical activities aimed at improving diagnostic accuracy and guiding treatment selection. Combines Nura Health's multi-modal biomarker signature and patient subtyping capabilities with Sur180's novel non-hormonal therapeutic development targeting the stress-response pathway.
• Ponce Health Sciences University (PHSU)coreStrategic or Co-development PartnerResearch collaboration partner for endometriosis research conducted primarily from Ponce, Puerto Rico. Collaborated on research published in Biology of Reproduction on novel non-hormonal therapeutic approach.
• Ponce Research Institute (PRI)coreStrategic or Co-development PartnerCollaborative research institution where Sur180 Therapeutics conducts its laboratory work and preclinical research. Houses Sur180 staff including research associates and laboratory supervisor.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• AbbVie: Markets Orilissa (elagolix), the leading oral GnRH antagonist approved for endometriosis pain. Operates a broad women's health portfolio and is the dominant incumbent Sur180's program would need to differentiate against.
• Myovant Sciences (Sumitomo Pharma): Developed Myfembree (relugolix), approved for endometriosis-associated pain, now commercialized globally through Sumitomo. Directly competitive on indication and target patient population, with established commercial infrastructure.
• Bayer: Markets Visanne (dienogest), a widely-used progestin for endometriosis. As a broad incumbent in women's health, Bayer represents both a competing commercial standard of care and a potential out-licensing or acquisition counterparty.
• Organon: Global women's health company spun out from Merck with established endometriosis assets and a commercial women's-health salesforce. Comparable business model focused on female-specific conditions.
• Crinetics Pharmaceuticals: Public clinical-stage endocrine-focused biotech developing small-molecule therapies for rare endocrine diseases. Comparable mechanism class (small molecule, endocrine targets) and translational development model, with substantially greater capital and clinical maturity.

Direct peers

• ObsEva: Swiss clinical-stage biotech that developed linzagolix, an oral GnRH antagonist for endometriosis. Most directly comparable company in endometriosis therapeutics development; provides reference points for clinical and regulatory risk.

Emerging players

• DotLab: Early-stage diagnostics company developing blood-based biomarkers for endometriosis. Comparable in scale and stage, with adjacent technology focus — illustrates the broader endometriosis-focused company ecosystem.
• NextGen Jane: Early-stage women's-health diagnostics company developing non-invasive endometriosis detection from menstrual blood. Comparable stage and patient-centric mission focused on closing the endometriosis diagnostic gap.
• Celmatix: Biotech developing therapeutics and diagnostics for women's reproductive health, including endometriosis. Operates a similar early-stage, women-led model with platform ambitions in reproductive medicine.
• Spruce Biosciences: Late-stage clinical rare-endocrine biotech. While focused on congenital adrenal hyperplasia, comparable as a small public rare-endocrine company with similar translational approach and small-team structure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/sur180tx
• LinkedInlinkedin.com/company/sur180tx
• Instagraminstagram.com/sur180tx
• Xx.com/sur180

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sur180 Therapeutics